Synapse - Works

Results (263)

Ttafasitamab plus lenalidomide (TAFA+LEN) versus pola-BR, r2, and CAR-T in non-transplant eligible (NTE) relapsed/refractory (r/r) DLBCL: A post hoc analysis of the RE-MIND2 study comparing multiple cohort-balancing approaches

Meeting Abstract

Córdoba, R.; Zinzani, P. L.; Joffe, E.; Yoon, D. H.; Peters, A.; Waltl, E. E.; Alvero, C.; Sabatelli, L.; Salles, G.; Nowakowski, G. S.
Value in Health (2022)

Fulltext@MSK | Save

Patient-reported outcomes following treatment with vimseltinib for tenosynovial giant cell tumour in a phase 2 expansion study

Meeting Abstract

Blay, J. Y.; Gelderblom, H.; Rutkowski, P.; Wagner, A. J.; van de Sande, M.; Stacchiotti, S.; Le Cesne, A.; Palmerini, E.; Vallee, M.; Harrow, B.; more...
Value in Health (2022)

Fulltext@MSK | Save

Matching-adjusted indirect comparison (MAIC) of tepotinib with capmatinib in previously treated advanced non-small cell lung cancer (aNSCLC) with met exon 14 (METex14) skipping

Meeting Abstract

Paik, P.; Pfeiffer, B.; Vioix, H.; Postma, M. J.
Value in Health (2022)

Fulltext@MSK | Save

Medical cannabis legalization and opioid- and pain- related outcomes among us patients newly diagnosed with cancer and receiving anti-cancer treatment

Meeting Abstract

Bao, Y.; Zhang, H.; Bruera, E.; Portenoy, R.; Rosa, W. E.; Reid, M. C.; Wen, H.
Value in Health (2022)

Fulltext@MSK | Save

Health care resource utilization with asciminib and bosutinib among adults with chronic myeloid leukemia in chronic phase previously treated with ≥2 tyrosine kinase inhibitors: Week 48 and week 96 results from ASCEMBL trial

Meeting Abstract

Cortes, J. E.; Sasaki, K.; Réa, D.; Mauro, M. J.; Tran, D.; Wang, P.; Jadhav, K.; Di Caprio, L.; Yocolly, A.
Value in Health (2022)

Fulltext@MSK | Save

Physician perceptions on the treatment and health-related quality of life burden of Endogenous Cushing's syndrome

Meeting Abstract

Wilson, G. P.; Oak, B.; Silber, A.; Meyer, J.; O'Hara, M.; Geer, E. B.
Value in Health (2022)

Fulltext@MSK | Save

Health state utility values and quality of life in patients receiving ripretinib in the phase 3 INVICTUS trial and a real-world evidence study in China

Meeting Abstract

Jones, R. L.; Blay, J. Y.; Chi, P.; Bauer, S.; Gelderblom, H.; Shen, L.; He, Y. L.; Heinrich, M. C.; Schöffski, P.; Zalcberg, J. R.; more...
Value in Health (2022)

Fulltext@MSK | Save

Follicular dendritic cell sarcoma of the chest

Editorial

Ilonen, I. K.; Meltzer, A. J.; Ellozy, S.; Bains, M. S.; Huang, J.
Annals of Thoracic Surgery (2022)

Fulltext@MSK | Save

(177)Lu and (227)Th Labeled 3,4,3-(LI-1,2-HOPO): Characterization, optimized synthesis, biological distribution and dosimetry

Meeting Abstract

Sanders, V.; Phipps, M.; Demoin, D.; Pratt, E.; Bhupathiraju, N. V. S. D.; Ponnala, S.; Ferdous, J.; Schlyer, D.; Carter, L.; Lewis, J.; more...
Nuclear Medicine and Biology (2022)

Fulltext@MSK | Save

Investigating different chelators for a pretargeting approach with (203:212)Pb- and (64:67)Cu-labeled tetrazines

Meeting Abstract

Bauer, D.; Michel, A.; Kaminsky, S.; Li, M. S.; Schultz, M.; Saini, S.; Lapi, S.; Lewis, J.
Nuclear Medicine and Biology (2022)

Fulltext@MSK | Save